New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
14:27 EDTVRXJublia could become Valeant's biggest product, says Jefferies
After Valeant announced FDA approval for Jublia, on schedule and as expected, Jefferies said the product targets an underserved market and could become the company's biggest drug. Jefferies sees peak worldwide sales for Jublia of $400M-$500M, but adds that its forecast could be conservative. The firm maintains its Buy rating and $154 price target on Valeant.
News For VRX From The Last 14 Days
Check below for free stories on VRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
09:07 EDTVRXAllergan filed answer in federal court reponding to Valeant, Pershing claims
Subscribe for More Information
August 27, 2014
13:33 EDTVRXValeant, Pershing suit against Allergan expedited, WSJ says
After a hearing on Wednesday morning in Delaware Chancery Court, a judge has expedited a lawsuit from Valeant (VRX) and Pershing Square's William Ackman against Allergan (AGN), says the Wall Street Journal. Last week Valeant and Ackman sued Allergan to quickly schedule a special meeting to decide on the fate of Allergan's board members, added the Wall Street Journal. Reference Link
August 26, 2014
20:04 EDTVRXAllergan requests block to Ackman, Valeant votes, announces Special Meeting date
Subscribe for More Information
16:45 EDTVRXAllergan schedules special meeting on takeover for December 18, WSJ says
Subscribe for More Information
August 22, 2014
19:02 EDTVRXAllergan confirms Pershing written request, board views Valeant offer inadequate
Subscribe for More Information
18:33 EDTVRXPershing Square submits requisite requests from Allergan holders to call meeting
Subscribe for More Information
09:33 EDTVRXValeant to request today special meeting of Allergan holders, CNBC reports
Valeant (VRX) will deliver today a request of 30%-plus of Allergan (AGN) shareholders for a special meeting, CNBC's David Faber reports, citing sources.
06:49 EDTVRXJudge rejects Allergan inquiry to quicken insider trading case, Reuters says
Subscribe for More Information
06:45 EDTVRXJudge refuses to prevent special Allergan shareholder meeting, NY Times says
Subscribe for More Information
August 21, 2014
09:42 EDTVRXValeant to sell Precision's assets related to two acne treatments
Subscribe for More Information
August 20, 2014
17:59 EDTVRXAllergan talks with Salix in defense tactic said to be dormant, Bloomberg says
Subscribe for More Information
17:35 EDTVRXAllergan said to explore options outside of Salix acquisition, Bloomberg says
Subscribe for More Information
10:53 EDTVRXAnalysts say Salix takeover would boost Allergan
Subscribe for More Information
09:46 EDTVRXAllergan merger deal not imminent, CNBC's Faber reports
An acquisition by Allergan (AGN) is not imminent, CNBC's David Faber reports. Salix (SLXP) and Jazz Pharmaceuticals (JAZZ) are said to be potential targets of the company, Faber adds. Valeant (VRX) could announce over the next few days that it has enough votes to call for a special meeting, the reported said.
07:07 EDTVRXSome Valeant shareholders express uncertainty over Allergan deal, Reuters says
Subscribe for More Information
August 19, 2014
17:14 EDTVRXOn The Fly: Closing Wrap
Subscribe for More Information
16:52 EDTVRXAllergan all-cash deal would reduce hostile bid chances, says BMO Capital
Subscribe for More Information
13:13 EDTVRXAllergan approached Salix, one other about takeover, WSJ reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use